Free Trial

5 Good Reasons it's Time to Buy High-Yield Dividend King 3M

3M stock price

Key Points

  • 3M stock trades at a decade-low while headwinds slow and evaporate. 
  • The stock offers deep value and high yield for investors willing to take on a little risk. 
  • There is concern the dividend may be cut, but it appears safe for now. 
  • 5 stocks we like better than 3M

3M NYSE: MMM is an interesting speculation on high-yield dividend growth and value, and now is an excellent time to take a bite. The company is navigating a difficult time with aplomb, and the market is putting in a bottom. The critical elements include the removal of uncertainty, a clearer financial outlook, a market-leading dividend yield, and a deep value for investors.

The risk is that a dividend cut may come, but a mitigating factor exists. If it comes, the dividend cut is most likely priced into the market, which is set up for a rebound this year. 

#1 - 3M Reaches Settlement in Hearing Loss Case 

Among 3M’s largest sources of uncertainty is the case concerning ear plugs and hearing loss. After years of litigation, the case is coming to a close. 3M reached a settlement for $6 billion that the board has approved. This is about half the expected $10 to $15 billion punted by analysts, dramatically changing the financial outlook. The money will paid out over 5 years; analysts view it as a positive. 

#2 - 3M Reaches Settlement in Forever Chemical Case 

Another headwind for 3M involves the use of forever chemicals or PFAS. 3M used forever chemicals to manufacture various products, including fire-fighting foam and non-stick coatings. The settlement is worth $12.5 billion and will be paid out over 13 years. Money will help municipalities test for and clean up suspected chemicals. Regarding revenue and earnings, the combined settlements are worth about 56% of the 2023 consensus revenue target and $33.50 per share in earnings. 

The company’s cash flow is robust. FCF is up significantly in 2023 and is expected to remain strong for the foreseeable future. The $1.5 billion reported for Q2 is sufficient to continue paying dividends and pay the settlements with the aid of the balance sheet. Dividends were worth $828 million in the quarter, leaving a significant amount available for “other” purposes.

The roughly $0.7 billion leftover, if only used to pay settlement costs, could take care of the $18.5 billion in less than 6 years, and the pre-tax charge for PFAS has already been logged.

#3 - 3M Pays a Royally Good Dividend 

3M is among the highest-quality Dividend Kings and has increased its payout annually for over 60 years. There is some concern that the company may need to cut the payment, but the risk is minimal now. The costs of settlements and payout ratio, about 65% of the consensus earnings estimate, may keep the pace of distribution increases low, but the 2.6% CAGR is sustainable.

Among the takeaways from the Q2 report were top and bottom-line outperformance and an increase in guidance. 

#4- 3M is a Value to Investors 

3M offers value to investors. Not only does it pay a high 6% dividend yield, the stock trades at a low 12X earnings. That’s below the S&P 500 NYSEARCA: SPY average and well below what investors typically pay for a Dividend King. Names like Stanley Black & Decker NYSE: SWK and The Coca-Cola Company NYSE: KO trade in a range of 18X to 25X while paying much lower yields, and there is a spin-off in the works. 

#5 - 3M Will Spin Off Medical Unit 

3M will spin off its medical unit this fall. The spin-off includes 3M med-tech units worth $8.4 billion in revenue in 2022. That puts it low on the list of med-tech companies regarding revenue, which is an opportunity for growth. Names like Baxter NYSE: BAX, Stryker NYSE: SYK, and Boston Scientific NYSE: BSX are doing about 1.5X the business, while Medtronic NYSE: MDT and Abbott Laboratories NYSE: ABT, which is more diversified, are 4 and 5 times as large.

These stocks also trade at considerably higher valuations, trading 15X to 27X their earnings. The spin-off should unlock value for shareholders. 

The Technical Outlook: 3M Bottoms at Decade Low 

The chart of 3M isn’t pretty. The market has trended lower for years due to the looming lawsuits that are now mostly completed. Price action appears to be putting in a bottom because of the altering outlook and a rebound could be coming. Price action is up following the board’s approval of the earplug settlement, and a move above the 150-day EMA is imminent. In that scenario, the market could enter a complete reversal and trend higher through the end of the year. 

3m stock chart

→ Get in before Reddit does (From Traders Agency) (Ad)

Should you invest $1,000 in 3M right now?

Before you consider 3M, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 3M wasn't on the list.

While 3M currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Thomas Hughes
About The Author

Thomas Hughes

Contributing Author

Technical and Fundamental Analysis

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Stryker (SYK)
4.7977 of 5 stars
4.80 / 5 stars
$339.37+0.4%0.94%38.74Moderate Buy$370.32
Baxter International (BAX)
4.4805 of 5 stars
4.48 / 5 stars
Medtronic (MDT)
4.9787 of 5 stars
4.98 / 5 stars
Intuitive Surgical (ISRG)
4.6127 of 5 stars
4.61 / 5 stars
$444.16+0.1%N/A80.17Moderate Buy$410.32
Stanley Black & Decker (SWK)
3.5943 of 5 stars
3.59 / 5 stars
Coca-Cola (KO)
4.29 of 5 stars
4.29 / 5 stars
$63.70+1.0%3.05%25.48Moderate Buy$70.00
Abbott Laboratories (ABT)
4.9659 of 5 stars
4.97 / 5 stars
$104.22+0.0%2.11%32.47Moderate Buy$120.18
Boston Scientific (BSX)
4.4183 of 5 stars
4.42 / 5 stars
$77.69+1.0%N/A65.29Moderate Buy$78.29
3M (MMM)
4.3779 of 5 stars
4.38 / 5 stars
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines